ASP2138 + Chemotherapy + Pembrolizumab for Stomach Cancer

This trial tests a new treatment, ASP2138, for stomach or gastroesophageal junction (GEJ) cancer that cannot be surgically removed or has metastasized. The study focuses on HER2-negative cancers with the CLDN18.2 protein. Researchers aim to determine if combining ASP2138 with chemotherapy and pembrolizumab can extend the time patients live without cancer progression compared to standard treatments. Individuals with locally advanced or metastatic gastric or GEJ cancer with these protein characteristics may qualify for this trial. Participants will not know if they receive ASP2138 or a placebo, a common practice to ensure unbiased results. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Research has shown that ASP2138 targets a specific protein called CLDN18.2, found in some gastric cancer tumors. However, earlier studies provide limited information about its safety. Since this trial is in a later phase, previous studies have found ASP2138 reasonably safe for humans, though its side effects and tolerance are still under evaluation.

The FDA has approved pembrolizumab for advanced stomach cancer. Research indicates it is generally well-tolerated, with manageable side effects when combined with chemotherapy. Common side effects include tiredness, nausea, and skin reactions.

5-FU (5-fluorouracil) is a chemotherapy drug commonly used to treat various cancers, including stomach cancer. It is known to be safe, with common side effects such as redness and pain on the palms and soles (hand-foot syndrome), tiredness, and nausea.

Capecitabine is another chemotherapy drug often used in combination treatments for gastric cancer. It is considered safe but can cause side effects like diarrhea, nausea, and hand-foot syndrome.

Oxaliplatin is a chemotherapy drug often used with 5-FU and capecitabine. It is generally well-tolerated but can sometimes cause nerve damage, leading to tingling or numbness in the hands and feet.

Researchers are excited about ASP2138 combined with pembrolizumab and chemotherapy for stomach cancer because it offers a fresh approach to tackling the disease. Unlike many standard treatments that primarily focus on chemotherapy agents like 5-FU and oxaliplatin, ASP2138 is a novel agent administered through a subcutaneous injection, potentially improving patient convenience and compliance. Additionally, by pairing ASP2138 with pembrolizumab, which is an immunotherapy, this regimen aims to harness the immune system to better target and fight cancer cells, offering hope for enhanced effectiveness over current options.

Research has shown that ASP2138, one of the treatments in this trial, might help treat stomach and gastroesophageal junction (GEJ) cancer by targeting a protein called CLDN18.2, found in some tumors. ASP2138 connects to both the CLDN18.2 protein and immune cells known as T cells, encouraging the immune system to attack the tumor. In this trial, some participants will receive ASP2138 with pembrolizumab and chemotherapy. Pembrolizumab, when combined with chemotherapy, has had mixed results in treating gastric cancer, but it remains under study. Some research suggests that treatments targeting CLDN18.2, like ASP2138, could help patients live longer without their cancer worsening. Early results from similar treatments have shown promise in delaying cancer progression.⁶⁷⁸⁹¹⁰